Key Data:
Project Type
Biologics facility
Output Chemicals
Humira (adalimumab) (CAT-derived human anti-TNFα [tumour necrosis factor α]) monoclonal antibody
Location
Barceloneta, Commonwealth of Puerto Rico
Estimated Investment
$450m (£336m)
Completion
2005 (then validation took until April 2007)
Key Players:
Sponsors
Abbott Laboratories, Abbott Biotechnology Ltd
General Contractor
Insulation Specialties, Pharmabio, Cives Steel Company Corp, Industrial Sprinklers
Financing
Abbott Laboratories and tax incentives from the Government of the Commonwealth of Puerto Rico